NCT06630416View on ClinicalTrials.gov

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 27, 2024

Primary Completion Date

May 10, 2029

Study Completion Date

May 10, 2030

Conditions
Metastatic Bladder Urothelial CarcinomaMetastatic Malignant Solid NeoplasmStage IV Bladder Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Pemetrexed

Given IV

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER